COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,761 Articles (22,502 medRxiv, 8,259 bioRxiv)

Most recent first Previous |  Page 2555: Articles 25541-25550  | Next

SARS-CoV-2 Neutralizing Antibody Responses Are More Robust in Patients with Severe Disease
Wang, P., Liu, L., Nair, M. S., Yin, M. T., Luo, Y., Wang, Q., Yuan, T., Mori, K., Solis, A. G., Yamashita, M., Purpura, L. J., Laracy, J. C., Yu, J., Sodroski, J., Huang, Y., Ho, D. D.
10.1101/2020.06.13.150250 — Posted: 2020-06-14
Single-cell screening of SARS-CoV-2 target cells in pets, livestock, poultry and wildlife
Chen, D., Sun, J., Zhu, J., Ding, X., Lan, T., Zhu, L., Xiang, R., Ding, P., Wang, H., Wang, X., Wu, W., Qiu, J., Wang, S., Li, H., An, F., Bao, H., Zhang, L., Han, L., Zhu, Y., Wang, X., Wang, F., Yuan, Y., Wu, W., Sun, C., Lu, H., Wu, J., Sun, X., Zhang, S., Sahu, S. K., Chen, H., Fang, D., Luo, L., Zeng, Y., Wu, Y., Cui, Z., He, Q., Jiang, S., Ma, X., Feng, W., Xu, Y., Li, F., Liu, Z., Chen, L., Chen, F., Jin, X., Qiu, W., Yang, H., Wang, J., Hua, Y., Liu, Y., Liu, H., Xu, X.
10.1101/2020.06.13.149690 — Posted: 2020-06-14
X-206 is a potent and selective inhibitor of SARS-CoV-2 infection in vitro
Svenningsen, E. B., Jensen, J. T., Cadanet, J. B., Liu, H., Lin, S., Villameriel, J. M., Paludan, S. R., Holm, C. K., Poulsen, T. B.
10.1101/2020.06.14.149153 — Posted: 2020-06-14
How to better communicate exponential growth of infectious diseases
Schonger, M., Sele, D.
10.1101/2020.06.12.20129114 — Posted: 2020-06-14
COVID-19 Deaths: Which Explanatory Variables Matter the Most?
Riley, P., Riley, A., Turtle, J., Ben-Nun, M.
10.1101/2020.06.11.20129007 — Posted: 2020-06-14 Discussion: Onsite
Multiplex Isothermal Amplification Coupled with Nanopore Sequencing for Rapid Detection and Mutation Surveillance of SARS-CoV-2
Bi, C., Ramos-Mandujano, G., Hala, S., Xu, J., Mfarrej, S., Alofi, F. S., Khogeer, A., Hashem, A. M., Almontashiri, N. A. M., Pain, A., Li, M.
10.1101/2020.06.12.20129247 — Posted: 2020-06-14
Global research trend in the treatment of the new Coronavirus diseases (COVID-19) : bibliometric analysis.
Mbogning Fonkou, M. D., YACOUBA, A.
10.1101/2020.06.13.20122762 — Posted: 2020-06-14
Assessment of spread of SARS-CoV-2 by RT-PCR and concomitant serology in children in a region heavily affected by COVID-19 pandemic
Cohen, R., Jung, C., Ouldali, N., Sellam, A., Batard, C., Cahn-Sellem, F., Elbez, A., Wollner, A., Romain, O., Corrard, F., Aberrane, S., Soismier, N., Creidy, R., Smati-Lafarge, M., Launay, O., Bechet, S., Varon, E., Levy, C.
10.1101/2020.06.12.20129221 — Posted: 2020-06-14
Asymptomatic and presymptomatic transmission of SARS-CoV-2: A systematic review
Savvides, C., Siegel, R.
10.1101/2020.06.11.20129072 — Posted: 2020-06-14 Discussion: Onsite
When is SARS-CoV-2 in your shopping list?
Hernandez Mejia, G., Hernandez-Vargas, E. A.
10.1101/2020.06.11.20128850 — Posted: 2020-06-14

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).